Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?

被引:110
作者
Baur, A
Stäbler, A
Nagel, D
Lamerz, R
Bartl, R
Hiller, E
Wendtner, C
Bachner, F
Reiser, M
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Clin Radiol, D-81377 Munich, Germany
[2] Univ Munich, Klinikum Grosshadern, Dept Clin Chem, D-81377 Munich, Germany
[3] Univ Munich, Klinikum Grosshadern, Dept Internal Med 2, D-81377 Munich, Germany
关键词
multiple myeloma; MRI; prognosis; staging system; spine; bone marrow; survival;
D O I
10.1002/cncr.10818
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. This study evaluated the prognostic value of a three-grade staging system of spinal involvement using magnetic resonance imaging (MRI) in patients with multiple myeloma and determined its usefulness as an independent parameter in the staging system of Durie and Salmon. METHODS. Seventy-seven previously untreated patients with multiple myeloma underwent MRI of the thoracic and lumbar spine with unenhanced T1-weighted spin echo and short-tau inversion time inversion recovery sequences. The patients were evaluated according to their infiltration patterns and the extent of bone marrow involvement was staged using a three-grade scale: Stage 1, no focal or diffuse infiltration; Stage II, 1-10 foci or mild diffuse infiltration; Stage III, more than 10 foci or strong diffuse infiltration. RESULTS. The infiltration patterns had no significant effect on survival. Of 77 patients, 25 would have been understaged using the standard staging system of Durie and Salmon without the findings of MRI and 8 patients would have been understaged if the staging was based only on MRI. The combination of the staging system of Durie and Salmon and MRI was highly significant with respect to survival (P < 0.0001, log rank analysis). MRI staging I-III was independent of the staging system of Durie and Salmon (Cox regression model). CONCLUSIONS. A three-grade staging of spinal MRI provides a significant prognostic tool for patients with multiple myeloma. The authors propose including it in the staging system of Durie and Salmon. (C) 2002 American Cancer Society.
引用
收藏
页码:1334 / 1345
页数:12
相关论文
共 43 条
[1]  
ALEXANIAN R, 1980, BLOOD, V56, P521
[2]  
ATTAL M, 1986, NEW ENGL J MED, V335, P91
[3]   THE ROLE OF T2-WEIGHTED GRADIENT-ECHO IN MRI DEMONSTRATION OF SPINAL MULTIPLE-MYELOMA [J].
AVRAHAMI, E ;
TADMOR, R ;
KAPLINSKY, N .
SPINE, 1993, 18 (13) :1812-1815
[4]   Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].
Barlogie, B ;
Desikan, R ;
Eddlemon, P ;
Spencer, T ;
Zeldis, J ;
Munshi, N ;
Badros, A ;
Zangari, M ;
Anaissie, E ;
Epstein, J ;
Shaughnessy, J ;
Ayers, D ;
Spoon, D ;
Tricot, G .
BLOOD, 2001, 98 (02) :492-494
[5]   High-dose therapy and innovative approaches to treatment of multiple myeloma [J].
Barlogie, B .
SEMINARS IN HEMATOLOGY, 2001, 38 (02) :21-27
[6]  
BATAILLE R, 1992, BLOOD, V80, P733
[7]   PROGNOSTIC FACTORS AND STAGING IN MULTIPLE-MYELOMA - A REAPPRAISAL [J].
BATAILLE, R ;
DURIE, BGM ;
GRENIER, J ;
SANY, J .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (01) :80-87
[8]   MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration [J].
Baur, A ;
Stabler, A ;
Bartl, R ;
Lamerz, R ;
Scheidler, J ;
Reiser, M .
SKELETAL RADIOLOGY, 1997, 26 (07) :414-418
[9]   A NEW PROGNOSTIC SYSTEM FOR MULTIPLE-MYELOMA BASED ON EASILY AVAILABLE PARAMETERS [J].
BLADE, J ;
ROZMAN, C ;
CERVANTES, F ;
REVERTER, JC ;
MONTSERRAT, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 72 (04) :507-511
[10]   MULTIPLE-MYELOMA - VMCP/VBAP ALTERNATING COMBINATION CHEMOTHERAPY IS NOT SUPERIOR TO MELPHALAN AND PREDNISONE EVEN IN HIGH-RISK PATIENTS [J].
BOCCADORO, M ;
MARMONT, F ;
TRIBALTO, M ;
AVVISATI, G ;
ANDRIANI, A ;
BARBUI, T ;
CANTONETTI, M ;
CAROTENUTO, M ;
COMOTTI, B ;
DAMMACCO, F ;
FRIERI, R ;
GALLAMINI, A ;
GALLONE, G ;
GIOVANGROSSI, P ;
GRIGNANI, F ;
LAUTA, VM ;
LIBERATI, M ;
MUSTO, P ;
NERETTO, G ;
PETRUCCI, MT ;
RESEGOTTI, L ;
PILERI, A ;
MANDELLI, F .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) :444-448